These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 29329521

  • 21. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.
    Diagn Pathol; 2016 Oct 07; 11(1):94. PubMed ID: 27717365
    [Abstract] [Full Text] [Related]

  • 22. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.
    Clin Exp Immunol; 2017 Feb 07; 187(2):304-315. PubMed ID: 27784126
    [Abstract] [Full Text] [Related]

  • 23. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.
    Gonzalez Suarez ML, Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Aeddula NR, Pivovarova AI, Chewcharat A, Bathini T, Mao MA, Basu A, Cheungpasitporn W.
    Med Sci (Basel); 2020 Oct 21; 8(4):. PubMed ID: 33096866
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM, Brophy PD.
    Curr Opin Pediatr; 2013 Apr 21; 25(2):225-31. PubMed ID: 23486421
    [Abstract] [Full Text] [Related]

  • 26. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
    Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M.
    Pediatr Nephrol; 2014 Jun 21; 29(6):1107-11. PubMed ID: 24408225
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ.
    Clin J Am Soc Nephrol; 2014 Nov 07; 9(11):1876-82. PubMed ID: 25341722
    [Abstract] [Full Text] [Related]

  • 31. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.
    Zhao F, Afonso S, Lindner S, Hartmann A, Löschmann I, Nilsson B, Ekdahl KN, Weber LT, Habbig S, Schalk G, Kirschfink M, Zipfel PF, Skerka C.
    Front Immunol; 2019 Nov 07; 10():1030. PubMed ID: 31214159
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis.
    Inman M, Prater G, Fatima H, Wallace E.
    Clin Kidney J; 2015 Aug 07; 8(4):445-8. PubMed ID: 26251714
    [Abstract] [Full Text] [Related]

  • 35. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez E, de la Cerda F, Pérez de José A, López I, Fernández L, Pérez Gómez V, Ávila A, Bravo L, Lumbreras J, Allende N, Sanchez de la Nieta MD, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, Illescas ML, Calvo C, Oviedo V, Da Silva I, Goicoechea de Jorge E, Caravaca F, Praga M, C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN).
    Am J Kidney Dis; 2021 May 07; 77(5):684-695.e1. PubMed ID: 33359150
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.
    Deshayes S, Martin Silva N, Chatelet V, Chantepie S, Le Quintrec M, Comoz F, Bridoux F, Dragon-Durey MA, Aouba A.
    Clin Rheumatol; 2018 Apr 07; 37(4):1119-1122. PubMed ID: 29516279
    [Abstract] [Full Text] [Related]

  • 38. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.
    Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT.
    Pediatr Nephrol; 2014 Jul 07; 29(7):1283-7. PubMed ID: 24464478
    [Abstract] [Full Text] [Related]

  • 39. Myeloperoxidase immunohistochemical staining can identify glomerular endothelial cell injury in dense deposit disease.
    Blatt NB, Kumar T, Wickman LT, Kanaan HD, Chang A, Zhang PL.
    Pediatr Nephrol; 2021 Dec 07; 36(12):4003-4007. PubMed ID: 34522991
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.